| Trial registration number
|
IRCT20201227049854N1 |
Full text link
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
http://en.irct.ir/trial/53327
|
First author
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Mehraban Sadeghi
|
Contact
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
vcrt@skums.ac.ir
|
Registration date
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
2021-07-11
|
Recruitment status
Last imported at : July 24, 2021, 9:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Completed
|
Study design
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
RCT
|
Allocation
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Randomized
|
Design
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Parallel
|
Masking
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Blind label
|
Center
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
single-center
|
Study aim
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Treatment
|
Inclusion criteria
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Patients with positive covid19 PCR test who have been treated with Remdesivir
Spo2<93%
Patient with lung infiltration
Absence of underlying liver disease
Liver enzymes less than 5 times normal
|
Exclusion criteria
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Increased liver enzymes more than 5 times normal
Patient dissatisfaction
Pregnant or lactating patients
Patients with glomerular filtration less than 50 mg / min
|
Number of arms
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
2
|
Funding
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Shahre-kord University of Medical Sciences
|
Inclusion age min
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
18
|
Inclusion age max
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
100
|
Countries
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Iran
|
Type of patients
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Severe/critical disease at enrollment
|
Severity scale
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
7: Severe/critical disease at enrollment
|
Total sample size
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
70
|
primary outcome
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Direct Billirubin
Total Billirubin
Aspartate Aminotransferase
Alanine Aminotransferase
Alkaline Phosphatase
|
Notes
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
|
Phase
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Phase 3
|
Arms
Last imported at : July 12, 2021, 11:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
[{"arm_notes": "", "treatment_id": 738, "treatment_name": "Livergol", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|